Secreted frizzled-related protein 3 (sFRP3) regulates antidepressant responses in mice and humans

• Type of Material: Article
• Authors: M-H Jang, Johns Hopkins University; Y Kitabatake, Johns Hopkins University; E Kang, Johns Hopkins University; H Jun, Johns Hopkins University; MV Pletnikov, Johns Hopkins University; KM Christian, Johns Hopkins University; R Hen, Columbia University; S Lucae, Max Planck Institute; Elisabeth B. Binder, Emory University; H Song, Johns Hopkins University; G-I Ming, Johns Hopkins University
• Language: English
• Date: 2013-09
• Publisher: Springer Nature [academic journals on nature.com]: Hybrid Journals
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2012 Macmillan Publishers Limited All rights reserved
• Final Published Version (URL): http://www.nature.com/mp/journal/v18/n9/full/mp2012158a.html
• Title of Journal or Parent Work: Molecular Psychiatry
• ISSN: 1359-4184
• Volume: 18
• Issue: 9
• Start Page: 957
• End Page: 958
• Grant/Funding Information: Dr Binder receives grant support from NIMH, Behrens-Weise Foundation and the Seventh Framework Program from the European Commission. Dr Binder is also a coinventor on the following patents: FKBP5: a novel target for antidepressant therapy (International publication number: WO 2005/054500) and Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments (International application number: PCT/EP2005/005194).
• Research Categories: Psychology, General; Biology, Neuroscience

Abstract

Major depression, a common mental illness affecting millions of people worldwide, is one of the leading causes of morbidity and has a significant economic cost. Although the mechanisms of action are not well understood, antidepressants, including serotonin-selective reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), have been used for the treatment of depression, anxiety and other psychiatric disorders. Here we identified a Wnt signaling inhibitor, secreted frizzled-related protein 3 (sFRP3), as a molecular target of antidepressant treatments in rodent models, and revealed the significant association of three single-nucleotide polymorphisms (SNPs) in FRZB (the sFRP3 human ortholog) with early antidepressant responses in a clinical cohort.